Abstract
Bivalent ligands of κ opioid agonists and antagonists, such as norBNI and BNI, are used as tools to elucidate the κ receptor characteristics. Bivalent ligands may also be effective analgesics although none have this far been used clinically. Structure-activity relationships (SAR) and molecular modeling led to the development of a more potent and selective kappa antagonist (5-guanidinylnaltrindole, GNTI). Novel homo and hetero bivalent ligands with high mixed κ/μ or mixed κ/δ affinity and intriguing pharmacological properties may eventually lead to useful analgesics with fewer adverse side effects. Bivalent ligands were also developed that could act as probes of the receptor-oligomerzation and organization phenomena. A structurally unique κ antagonist (JDTic) provides an additional tool to characterize κ opioid receptor.
Keywords: Opioid Receptor, Naltrexamine, Kappa agonists, Analgesics, KDN-21
Current Topics in Medicinal Chemistry
Title: Kappa Receptor Bivalent Ligands
Volume: 7 Issue: 4
Author(s): Xuemei Peng and John L. Neumeyer
Affiliation:
Keywords: Opioid Receptor, Naltrexamine, Kappa agonists, Analgesics, KDN-21
Abstract: Bivalent ligands of κ opioid agonists and antagonists, such as norBNI and BNI, are used as tools to elucidate the κ receptor characteristics. Bivalent ligands may also be effective analgesics although none have this far been used clinically. Structure-activity relationships (SAR) and molecular modeling led to the development of a more potent and selective kappa antagonist (5-guanidinylnaltrindole, GNTI). Novel homo and hetero bivalent ligands with high mixed κ/μ or mixed κ/δ affinity and intriguing pharmacological properties may eventually lead to useful analgesics with fewer adverse side effects. Bivalent ligands were also developed that could act as probes of the receptor-oligomerzation and organization phenomena. A structurally unique κ antagonist (JDTic) provides an additional tool to characterize κ opioid receptor.
Export Options
About this article
Cite this article as:
Peng Xuemei and Neumeyer L. John, Kappa Receptor Bivalent Ligands, Current Topics in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/156802607779941251
DOI https://dx.doi.org/10.2174/156802607779941251 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recombinant Rhabdoviruses as Potential Vaccines for HIV-1 and Other Diseases
Current HIV Research Epilepsy, Regulation of Brain Energy Metabolism and Neurotransmission
Current Medicinal Chemistry Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Chalcones as Promising Lead Compounds on Cancer Therapy
Current Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Targeted Lipid Nanoparticles for Antisense Oligonucleotide Delivery
Current Pharmaceutical Biotechnology Establishment of Cholinergic Neuron-like Cell Lines with Differential Vulnerability to Nitrosative Stress
Current Neurovascular Research Therapy in Prion Diseases: From Molecular and Cellular Biology to Therapeutic Targets
Infectious Disorders - Drug Targets Pregnane X Receptor and its Potential Role in Drug Resistance in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Histone Modifications, Stem Cells and Prostate Cancer
Current Pharmaceutical Design Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology Inhibition of Brain Phospholipase A2 by Antimalarial Drugs: Implications for Neuroprotection in Neurological Disorders
Medicinal Chemistry Reviews - Online (Discontinued) The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Pharmacological and Biological Activities of Benzazepines: An Overview
Current Bioactive Compounds Erythropoietin and Oxidative Stress
Current Neurovascular Research Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Recent Developments in Patented DC-Based Immunotherapy for Various Malignancies
Recent Patents on Regenerative Medicine The Urokinase Receptor Interactome
Current Pharmaceutical Design The Mitochondriotropic Effects of L-carnitine and its Esters in the Central Nervous System
Current Medicinal Chemistry - Central Nervous System Agents